On the Current Connection and Relation Between Health Informatics and Social Informatics.

J Med Internet Res

Faculty of Social Sciences, University of Ljubljana, Ljubljana, Slovenia.

Published: September 2022

Scholars from the health and medical sciences have recently proposed the term social informatics (SI) as a new scientific subfield of health informatics (HI). However, SI is not a new academic concept; in fact, it has been continuously used in the social sciences and informatics since the 1970s. Although the dominant understanding of SI was established in the 1990s in the United States, a rich international perspective on SI has existed since the 1970s in other regions of the world. When that perspective is considered, the fields of understanding can be structured into 7 SI schools of thought. Against that conceptual background, this paper contributes to the discussion on the relationship between SI and HI, outlining possible perspectives of SI that are associated with health, medical, and clinical aspects. This paper argues against the multiplication and inconsistent appearance of the term SI when newly used in health and medical sciences. A more explicit name for the area that uses health and social data to advance individual and population health might be helpful to overcome this issue; giving an identity to this new field would help it to be understood more precisely and bring greater separation. This labeling could be fruitful for further segmentation of HI, which is rapidly expanding.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557763PMC
http://dx.doi.org/10.2196/40547DOI Listing

Publication Analysis

Top Keywords

health medical
12
health informatics
8
social informatics
8
medical sciences
8
health
7
informatics
5
current connection
4
connection relation
4
relation health
4
social
4

Similar Publications

Background: Whether a detected virus or bacteria is a pathogen that may require treatment, or is merely a commensal 'passenger', remains confusing for many infections. This confusion is likely to increase with the wider use of multi-pathogen PCR.

Objectives: To propose a new statistical procedure to analyse and present data from case-control studies clarifying the probability of causality.

View Article and Find Full Text PDF

Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies.

Discov Oncol

January 2025

Division of Hematology/Oncology, The University of Texas Health Sciences Center at Houston, McGovern Medical School, 6431 Fannin Street, MSB 5.216, Houston, TX, 77030, USA.

The established protocol for the management of acute myeloid leukemia (AML) has traditionally involved the administration of induction chemotherapy, followed by consolidation chemotherapy, and subsequent allogeneic stem cell transplantation for eligible patients. However, the prognosis for individuals with relapsed and refractory AML remains unfavorable. In response to the necessity for more efficacious therapeutic modalities, targeted immunotherapy has emerged as a promising advancement in AML treatment.

View Article and Find Full Text PDF

In 2017, Kidney Disease: Improving Global Outcomes (KDIGO) published a Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Since then, new lines of evidence have been published related to evaluating disordered mineral metabolism and bone quality and turnover, identifying and inhibiting vascular calcification, targeting vitamin D levels, and regulating parathyroid hormone. For an in-depth consideration of the new insights, in October 2023, KDIGO held a Controversies Conference on CKD-MBD: Progress and Knowledge Gaps Toward Personalizing Care.

View Article and Find Full Text PDF

ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.

Cytotherapy

January 2025

Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.

View Article and Find Full Text PDF

Factors Influencing Knowledge-Action Gap in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease: A Qualitative Study.

J Nutr Educ Behav

January 2025

Department of Fundamental and Community Nursing, School of Nursing, Nanjing Medical University, Nanjing, Jiangsu, China. Electronic address:

Objective: To explore the knowledge-action gap regarding health behaviors and their influencing factors among patients with metabolic dysfunction-associated fatty liver disease (MAFLD), using the Health Belief Model as a theoretical framework.

Design: A qualitative approach was adopted, involving semistructured interviews with individuals with MAFLD.

Setting: Participants were recruited from a community hospital and a tertiary hospital in Nanjing, China, between July and October 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!